Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy

Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ATH434-202 in individuals with multiple system atrophy (MSA).

The trial involved evaluating patients with more advanced disease than studied earlier in the double-blind Phase 2 trial ATH434-201. The oral drug demonstrated a clinical benefit in areas of impairment in multiple system atrophy, while also stabilizing biomarkers that underpin the pathology of the disease.

In a press release shared on July 28, Alterity Therapeutics Limited (NASDAQ:ATHE) said that the open-label study featured 10 participants who were diagnosed with the disease. They were treated with 75 mg of ATH434 twice daily for 12 months. At the conclusion of the trial, investigators observed an increase in mean (SD) UMSARS scores increased by 3.5 (4.7) points. The findings compared favorably to a prior study on a similar MSA population.

Moreover, about 43% of the patients who completed the trial were reported to have stable UMSARS scores, while 30% of the participants had stable neurological symptoms during the course of the trials.

David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics Limited (NASDAQ:ATHE) shared the following remarks on the results:

“I am very encouraged by the positive results from the ATH434-202 trial, as they reinforce the robust efficacy we observed in our double-blind study. The data from our Phase 2 studies are consistent and strongly support advancing our ATH434 program in MSA. With the favorable clinical and biomarker outcomes we have seen, we continue to believe that ATH434 has the potential to slow the progression of this devastating disease. We are committed to bringing this new therapy to patients as soon as possible.”

Alterity Therapeutics Limited (NASDAQ:ATHE) is a clinical-stage biotechnology company developing treatments for patients with neurodegenerative diseases.

While we acknowledge the potential of ATHE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now.

Disclosure: None.